• All
  • Anesthesiology
  • Anti-infectives and immunology
  • Biologicals
  • Blood disorders
  • Cardiovascular
  • CNS
  • Diabetes
  • Endocrinology/Sexual health
  • Gastrointestinal Diseases
  • General modelling
  • Lung Diseases
  • Methods
  • Oncology
  • Paediatrics
  • Pain
  • Peripheral Nervous System
  • Safety pharmacology

Noort van M., Ruppert M., DeJongh J., Marostica E., Bosch R., Mešic´ E., Snelder N. User-friendly parameter identifiability methods with a workflow to guide model development, using categorical and continuous scales. PAGE 2024 [Link to publication]

Marostica E., Ahsman M., Bragt van T., Noukens J., Vis P., T’joen C., Ulrichts P., Guglietta A., Rossenu S., Steeg van T. Population analysis of MG-ADL total score for efgartigimod Phase 3 study in myasthenia gravis patients: application of a bounded-integer model. PAGE 2024 [Link to publication]

Zeiser S., Rietveld P., Rijcken C., Snelder N. A population PK analysis of docetaxel after IV administration of CPC634 (CriPec® docetaxel) and generic docetaxel in plasma and tumor. PAGE 2024 [Link to publication]

Rietveld P,  Koolen S L.W. , Zeiser S., Snelder N., Rijcken C.J. , Koch B.C.P., Mathijssen R.H.J. , Sassen S.D.T. The effect of pH on intratumoural docetaxel release from polymeric nanoparticle CPC634. PAGE 2024 [Link to publication]

Bosch R., Petrone M., Arends R., Sijbrands E.J.G., Hoefman S.,  Snelder N. From In Vitro Efficacy to Long-term HbA1c Response for GLP-1R/GlucagonR Agonism using the 4GI-HbA1c Systems Model. PAGE 2024 [Link to publication]

Keunecke A., Goulooze S.C, Post T.M., Melhem M., Struemper H., Wang T. Case study of Exposure-Safety analysis in Phase 1 oncology – lessons learned. PAGE 2024 [Link to publication]

Goulooze S.C., Krekels E.H.J., Noort van M., Knibbe C.A.J. The drug titration paradox in the presence of intra-individual variation: can we estimate the true concentration-effect relationship? PAGE 2024 [Link to publication]

Goulooze S.C, Snelder N. Time-varying covariates, mediation analysis and overadjustment bias in PK/PD modelling. PAGE 2024 [Link to publication]

Wu Y.,  Völler S., Goulooze S.C.,  Allegaert K., Sherwin C.M. T., Rongen van A., Roofthooft  D.W.E., Simons S.H.P., Tibboel D., Flint R.B., Anker van den J.N.,  Knibbe C.A.J. Novel maturation function to capture the maturation of hepatic clearance in Preterm and Term Neonates to older infants, children and Adults: application to paracetamol and metabolites PK. PAGE 2024 [Link to publication]

Vendel E., Noort van N.,  Vis P., Liefaard L., Dimelow R. Belimumab Pharmacokinetic Simulations to Select an Appropriate Subcutaneous Dosing Regimen to Treat Paediatric Patients with Active Lupus Nephritis. PAGE 2024 [Link to publication]

Berkhout J., Fairman D., Noort van Noort, and Steeg van T.J. A model-based approach to predict SC administration and free target dynamics for monoclonal antibodies using PK and total target measurements after IV administration. PAGE 2024 [Link to publication]

Goulooze S.C., Yang S, Mesic E, Beerahee M, Post T.M, Mahar K.M.

Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]

Goulooze S.C., Noort van M., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M.

Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration based dosing, applied to a population dose hemoglobin model for Jesduvroq (daprodustat). PAGE 2023 [Link to publication]

Noort van M., DeJongh J.
Two New User-Friendly Approaches to Assess Pharmacometric Model Identifiability. PAGE 2023 [Link to publication]

Bosch R., Snelder N.

Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight. PAGE 2023 [Link to publication]